May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Voriconazol: A New Therapeutic Option for Paecilomyces Lilacinus Endophthalmitis
Author Affiliations & Notes
  • E. Oueghlani
    Eye Clinic, Univ Hosp Geneva, Geneva, Switzerland
  • E. Baglivo
    Eye Clinic, Univ Hosp Geneva, Geneva, Switzerland
  • K. Bouchuiguir-Wafa
    Infectious Disease Department, Univ Hosp Geneva, Geneva, Switzerland
  • C. Pournaras
    Infectious Disease Department, Univ Hosp Geneva, Geneva, Switzerland
  • D. Lew
    Infectious Disease Department, Univ Hosp Geneva, Geneva, Switzerland
  • A.B. Safran
    Infectious Disease Department, Univ Hosp Geneva, Geneva, Switzerland
  • Footnotes
    Commercial Relationships  E. Oueghlani, None; E. Baglivo, None; K. Bouchuiguir-Wafa, None; C. Pournaras, None; D. Lew, None; A.B. Safran, None.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 1412. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      E. Oueghlani, E. Baglivo, K. Bouchuiguir-Wafa, C. Pournaras, D. Lew, A.B. Safran; Voriconazol: A New Therapeutic Option for Paecilomyces Lilacinus Endophthalmitis . Invest. Ophthalmol. Vis. Sci. 2003;44(13):1412.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Paecilomyces lilacinus (PL) is a saprophyte fungus usually found in vegetables, fruit, soil. It is a rare cause of ocular infection. As a rule, visual outcome of PL endophtalmitis is poor, patients losing vision in the affected eyes. The organism is resistant to the usually available antifungal agents such as amphotericin B and fluconazol. We report the clinical observation of a PL endophthalmitis successfully treated with voriconazol, a new triazol molecule. To our knowledge, this is the first case of PL endophtalmitis ever treated with this new triazol antifungal agent. Methods: A 61 years old woman was referred for progressive visual loss and pain in the right eye (RE). Symptoms appeared 9 days after a secondary IOL (Artisan ®) implantation. Ophthalmological examination showed 20/200 visual acuity in the RE, a perikeratic circle, severe anterior chamber inflammation and mild vitreous inflammation. Results: A diagnosis of bacterial endophthalmitis was presumed, and the patient received imipenem and ofloxacin intraveinously in association with intra-vitreal injections of vancomicin and ceftazidim, and topical administration of garamicin and ofloxacin. Vitreous and aqueous humor cultures were negative for both fungi and either aerobes or anaerobes bacteria. A slight clinical improvement allowed the interruption of the intravenous and intravitreal antibiotical therapy. One month later, a second episode of endophtalmitis appeared (RE), vitreous cultures were performed again and then demonstrated the presence of PL. The fungigram for PL showed that fungi were resistant to amphotericin B ( MIC > 16 µg/ml), moderately susceptible to itraconazole (MIC 0.5 µg/ml) and susceptible to voriconazole (MIC 0.25 µg/ml). The patient was then treated, orally, with voriconazole 400mg, biq, for 4 months. Four months after the onset of voriconazol treatment, RE visual acuity had improved to 20/50. Conclusions: This observation emphasizes that PL endophthalmitis must be considered in post-surgical inflammation resistant to a regular antibacterial/antifungal therapy. Voriconazole, a new triazole antifungal molecule, appears to be efficient in such cases.

Keywords: endophthalmitis • fungal disease • antibiotics/antifungals/antiparasitics 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×